Summary
Immunohistochemical techniques were used to investigate leucocyte subpopulations in the bladders of patients with superficial transitional cell carcinoma treated with BCG Pasteur. Leucocyte subsets were enumerated with a panel of monoclonal antibodies which included CD3, CD4, CD8, TQ1, Leu7, CD15, HLA-DR, CD25, CD22. We demonstrated in the bladders of patients treated with BCG a particular lymphocyte population; the major subset was an inducer (CD4+, TQ1-) which was activated (CD25+, HLA-DR+) and associated with polymorphonuclear eosinophils. There was neither inducer of suppression nor major cytotoxic/suppressive subsets. CD8+ and NK cells could not be the primary mediators of BCG activity. These data supported the hypothesis of a helper T lymphocyte activity associated with lymphokine production and activation of effector killer cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fleischmann J, Wallis R, Toosi Z, Ellner J (1986) Urinary interleukin production in response to BCG therapy. J Urol 135:123A
Gardiner RA, Seymour GJ, Lavin MF, Strutton GM, Gemmell E, Hazan G (1986) Immunohistochemical analysis of the human bladder. Br J Urol 58:19–25
Guinan P, Crispen R, Rubenstein M (1987) BCG in management of superficial bladder cancer. Urology 30:515–519
Guinan P, Shaw M, Ray V (1986) Histopathology of BCG and thiotepa treated bladders. Urol Res 14:211–215
Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136:970–974
Kelley DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM, Catalona WJ, Ratliff TL (1986) Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical Bacillus Calmette-Guérin. J Urol 135:268–271
Khanna OP, Son DL, Mazer H, Read J, Nugent D, Cottone R, Heeg M, Rezvan M, Viek N, Friedmann M (1987) Superficial bladder cancer treated by intravesical Bacillus Calmette-Guérin or adriamycin: multicenter study interim report. Urology 30:520–528
Lage JM, Bauer WC, Kelley DR, Ratliff TL, Catalona WJ (1986) Histological parameters and pitfalls in the interpretation of bladder biopsies in Bacillus Calmette-Guérin treatment of superficial bladder cancer. J Urol 135:916–919
Lamm DL (1985) Bacillus Calmette-Guérin immunotherapy for bladder lancer. J Urol 134:40–47
Merguerian PA, Donahue L, Cockett ATK (1987) Intraluminal interleukin 2 and Bacillus Calmette-Guérin for treatment of bladder cancer: a preliminary report. J Urol 137:216–219
Ratliff TL, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent imune response for BCG-mediated antitumor activity. J Urol 137:155–158
Shaw M, Ray V (1986) Further evaluation of BCG and thiotepa therapy: immunohistologic analysis by monoclonal antibodies. J Urol 135:127A
Steg A, Leleu C, Boccon-Gibod L, Debre B (1986) Traitement des tumeurs superficielles et des carcinomes in situ de vessie par BCG-thérapie intra-vésicale. Ann Urol 20:26–32
Young JD, Peterson CGB, Venge P, Ohn ZA (1986) Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 321:613–616
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peuchmaur, M., Benoit, G., Vieillefond, A. et al. Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guerin. Urol. Res. 17, 299–303 (1989). https://doi.org/10.1007/BF00262987
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00262987